Yusuke Kyoden, Sumihito Tamura, Yasuhiko Sugawara, Noriyo Yamashiki, Yuichi Matsui, Junichi Togashi, Junichi Kaneko, Norihiro Kokudo, Masatoshi Makuuchi – 30 January 2008 – Previous reports described the effectiveness of living donor liver transplantation (LDLT) for post‐Kasai biliary atresia (BA) in the pediatric population. Information on the outcome of LDLT in patients that have reached adulthood after the Kasai procedure, however, is limited. A recent report postulated a poorer long‐term outcome of LDLT in these adults.

Masahiko Taniguchi, Tsuyoshi Shimamura, Hiroyuki Furukawa, Satoru Todo – 30 January 2008

Carla W. Brady, Alastair D. Smith, Karen M. Stechuchak, Cynthia J. Coffman, Janet E. Tuttle‐Newhall, Dawn Provenzale, Andrew J. Muir – 30 January 2008 – In the current system of allocation, patients awaiting orthotopic liver transplantation (OLT) remain at risk of developing de novo hepatocellular carcinoma (HCC) and removal from the waiting list. Using the United Network for Organ Sharing database, we calculated the rate and identified predictors of de novo HCC in patients listed for OLT between February 2002 and December 2004. Among 8566 patients, 1167 (13.6%) developed de novo HCC.

Mary Amanda Dew, Andrea F. DiMartini, Jennifer Steel, Annette De Vito Dabbs, Larissa Myaskovsky, Mark Unruh, Joel Greenhouse – 30 January 2008 – For patients receiving liver or other organ transplants for diseases associated with substance use, risk for relapse posttransplantation is a prominent clinical concern. However, there is little consensus regarding either the prevalence or risk factors for relapse to alcohol or illicit drug use in these patients.

Phunchai Charatcharoenwitthaya, Keith D. Lindor – 30 January 2008

Salvatore Gruttadauria, Giovanni Vizzini, Domenico Biondo, Lucio Mandalà, Riccardo Volpes, Ugo Palazzo, Bruno Gridelli – 30 January 2008 – This study presents our experience with the use of extended criteria donor (ECD) liver grafts. One hundred fifteen liver transplants were divided into 2 groups: standard (S) and nonstandard (NS). Fifty‐eight patients in group S received a liver procured from an ideal donor, whereas 57 patients in group NS received an organ from an ECD.

Jeffrey Campsen, Michael A. Zimmerman, James F. Trotter, Michael Wachs, Thomas Bak, Tracy Steinberg, Igal Kam – 30 January 2008 – Orthotopic liver transplantation (OLT) is the treatment of choice for patients with end‐stage primary sclerosing cholangitis (PSC). This study sought to chronicle the natural history of PSC recurrence following OLT and identify clinical variables that may contribute to disease reemergence. From 1988 to 2006, 1102 OLTs were performed in 1032 adults at the University of Colorado Health Sciences Center.

Andrew Mitchell, Leon A. Adams, Gerry MacQuillan, Jon Tibballs, Rohan vanden Driesen, Luc Delriviere – 30 January 2008 – Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease characterized by mucocutaneous and visceral telangiectasia. Hepatic involvement with vascular malformations may lead to portal hypertension, biliary ischemia, and high‐output cardiac failure. Liver transplantation is indicated for life‐threatening disease but carries significant risk from surgery and chronic immunosuppression.

Nina Singh, Cheryl Wannstedt, Lois Keyes, Debra Mayher, Lisa Tickerhoof, Mohamed Akoad, Marilyn M. Wagener, Thomas V. Cacciarelli – 30 January 2008 – The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus (CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient‐negative/donor‐positive (R−/D+) liver transplant recipients. Of 187 consecutive liver transplant recipients at our institution since July 2001, 36 (19.2%) belonged to the R−/D+ group.

Beyhan Demirhan, Banu Bilezikçi, A. Nihan Haberal, Şinasi Sevmiş, Zübeyde Arat, Mehmet Haberal – 30 January 2008 – During the first episode of acute cellular rejection (ACR) after liver transplantation, centrilobular changes in liver biopsy specimens may be possible indicators of subsequent episodes of ACR, early chronic rejection, or acute graft loss.